| Emily Claire Scranton, LPC-A | |
|
435 E Main St, Ansonia, CT 06401-1964 | |
| (203) 736-2601 | |
| Not Available |
| Full Name | Emily Claire Scranton |
|---|---|
| Gender | Female |
| Speciality | Counselor - Professional |
| Location | 435 E Main St, Ansonia, Connecticut |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629738752 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YP2500X | Counselor - Professional | 5157 (Connecticut) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Emily Claire Scranton, LPC-A 70 Martin St, West Haven, CT 06516-5029 Ph: (203) 671-1132 | Emily Claire Scranton, LPC-A 435 E Main St, Ansonia, CT 06401-1964 Ph: (203) 736-2601 |
News Archive
Fighting chemoresistant cancer remains a huge challenge that scientists are tackling from as many angles as they can. One alternative approach involves pairing two groups of compounds - pain medicine and metal ions - that have individually shown promise as anti-cancer agents. Scientists report in the ACS journal Inorganic Chemistry that combining the two led to new compounds that could destroy drug-resistant cancer cells and leave most normal cells alone in lab tests.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of gastric cancer, Roche/Genentech/ Chugai's Herceptin as an add-on to standard chemotherapy earns Decision Resources' proprietary clinical gold standard status in 2013, following its approval for the first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive gastric cancer in 2010.
An EU-funded project on migraines has not only taken researchers a step closer to understanding the causes of these incapacitating attacks, but has created a critical mass, reinforcing Europe's reputation of excellence in this field, and reassuring migraine sufferers that their condition is being taken seriously.
Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Novelos entered into a definitive agreement with Purdue Pharma L.P., an existing investor, to sell 13,636,364 shares of its common stock and warrants, expiring on December 31, 2015, to purchase an aggregate of approximately 4,772,728 shares of common stock at an exercise price of $0.66 per share, for gross proceeds of $9 million.
› Verified 6 days ago
Jaclyn Ann Evans, PSY.D. Counselor Medicare: Not Enrolled in Medicare Practice Location: 435 E Main St, Ansonia, CT 06401 Phone: 203-736-2905 | |
Ms. Kathleen D Riccio, BS, CAC Counselor Medicare: Not Enrolled in Medicare Practice Location: 435 E Main St, Ansonia, CT 06401 Phone: 203-736-2601 Fax: 203-736-2641 | |
Audrey Baehr, LADC Counselor Medicare: Not Enrolled in Medicare Practice Location: 121 Wakelee Avenue, Acs, Ansonia, CT 06401 Phone: 203-503-3650 Fax: 203-503-3659 | |
Mario Ramirez, Counselor Medicare: Not Enrolled in Medicare Practice Location: 170 N State St, Ansonia, CT 06401 Phone: 475-800-4779 | |
Lauren M Hickson, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 121 Wakelee Ave, Ansonia, CT 06401 Phone: 203-503-3650 Fax: 203-503-3659 | |
Mrs. Jaina Harris, B.S. Counselor Medicare: Not Enrolled in Medicare Practice Location: 205 Wakelee Ave, Ansonia, CT 06401 Phone: 203-735-7481 | |
Nicole Commercio, Counselor Medicare: May Accept Medicare Assignments Practice Location: 121 Wakelee Ave, Ansonia, CT 06401 Phone: 203-503-3650 Fax: 203-503-3659 |